sarepta - Search News

Order byBest matchMost fresh

Sarepta Will Resume Gene Therapy Shipments

Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault.

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne muscular dystrophy drug, but analysts worry it will take time for patients and doctors to feel safe using it.

· 22h · on MSN

Sarepta will resume gene therapy shipments after FDA review of recent patient death

PharmExec · 1h

Sarepta Stock On the Rise Following Resumption of Elevidys Shipments in US

· 6h

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

Shares of Sarepta surged Tuesday, a day after the FDA said the company could lift a voluntary pause on shipments of its Elevidys drug, which had been linked to three patient deaths this year.

· 23h

FDA allows Sarepta to resume some Elevidys shipments

· 9h

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

· 11h

Sarepta's FDA woes raise questions for future of gene therapy treatments

While Sarepta’s challenges could push some away from investing in gene therapies, it could also lead to interest in different approaches.

· 20h

FDA recommends lifting voluntary hold on Elevidys in ambulatory patients

· 1d

Parents call on FDA for path forward after Duchenne's gene therapy pause | Morning in America

Stock Movers: Sarepta, UPS, Whirlpool

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Sarepta: SRPT Stock To $40?

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially double from current levels to around $40

1hon MSN

Sarepta Therapeutics, Inc. (SRPT): “You Don’t Court Homicide,” Says Jim Cramer

We recently published 11 Stocks That Jim Cramer Recently Talked About. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer recently discussed.

STAT7h

Pharmalittle: We’re reading about a new Novo Nordisk CEO, an FDA reversal on Sarepta, and more

Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and president

35m

SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More Movers - Barron's

Revenue at SoFi jumps 44%, UnitedHealth slides after restoring financial guidance, and Sarepta soars after being notified by the FDA the company may lift its voluntary pause on shipments of Elevidys for ambulatory patients with Duchenne muscular dystrophy.

Explore more

Elevidys

gene therapy

Food and Drug Administration

Duchenne muscular dystrophy

Business Wire1d

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT).

Sarepta Will Resume Gene Therapy Shipments

Related Searches